UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 22 von 697
Datensatz exportieren als...
BibTeX
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action
Neurourology and urodynamics, 2011-03, Vol.30 (3), p.292-301
Andersson, Karl-Erik
de Groat, William C.
McVary, Kevin T.
Lue, Tom F.
Maggi, Mario
Roehrborn, Claus G.
Wyndaele, Jean Jacques
Melby, Thomas
Viktrup, Lars
2011
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Andersson, Karl-Erik
de Groat, William C.
McVary, Kevin T.
Lue, Tom F.
Maggi, Mario
Roehrborn, Claus G.
Wyndaele, Jean Jacques
Melby, Thomas
Viktrup, Lars
Titel
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: Pathophysiology and mechanism(s) of action
Ist Teil von
Neurourology and urodynamics, 2011-03, Vol.30 (3), p.292-301
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2011
Quelle
MEDLINE
Beschreibungen/Notizen
Background The PDE5 inhibitor tadalafil is investigation for the treatment of lower urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Several clinical studies of tadalafil and other PDE5 inhibitors have reported significant symptom reduction but limited urinary flow rate improvement. This manuscript reviews the published literature describing the pathophysiology of male LUTS, with an emphasis on mechanisms that may be modulated or improved by phosphodiesterase type 5 (PDE5) inhibition. Methods Literature (through March 2010) was obtained via Medline searches and from the individual reviewers files. Articles were selected for review based on describing in vitro, preclinical, or clinical studies of pathological processes contributing to LUTS, or possible effects of PDE5 inhibition in the lower urinary tract. Results Major mechanisms contributing to LUTS include: reduced nitric oxide/cyclic guanosine monophosphate signaling; increased RhoA kinase pathway activity; autonomic overactivity; increased bladder afferent activity; and pelvic ischemia. Tadalafil and other PDE5 inhibitors have demonstrated beneficial effects on smooth muscle relaxation, smooth muscle and endothelial cell proliferation, nerve activity, and tissue perfusion that may impact LUTS in men. Conclusions The pathophysiology of male LUTS is complex and not completely understood. LUTS may occur independently of BPH or secondary to BPH but in both cases involve obstructive or irritative mechanisms with substantial pathophysiological overlap. While the precise mechanism remains unclear, inhibition of PDE5 seems to have an effect on several pathways that may impact LUTS. Neurourol. Urodynam. 30:292–301, 2011. © 2011 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0733-2467
eISSN: 1520-6777
DOI: 10.1002/nau.20999
Titel-ID: cdi_proquest_miscellaneous_857811148
Format
–
Schlagworte
Carbolines - therapeutic use
,
Evidence-Based Medicine
,
Humans
,
Male
,
PDE5 phosphodiesterases
,
Phosphodiesterase 5 Inhibitors - therapeutic use
,
prostatic hyperplasia
,
Prostatic Hyperplasia - complications
,
Prostatic Hyperplasia - physiopathology
,
Recovery of Function
,
Signal Transduction - drug effects
,
Tadalafil
,
Treatment Outcome
,
urinary tract
,
Urodynamics - drug effects
,
Urologic Diseases - drug therapy
,
Urologic Diseases - etiology
,
Urologic Diseases - physiopathology
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX